<p>Spero Therapeutics（纳斯达克代码：SPRO - 获取免费报告）在华尔街 Zen 的股票分析师的研究报告中，将其评级从 “买入” 下调至 “持有”，该报告于周六发给客户和投资者。</p>
<p>获取 <strong>Spero Therapeutics</strong> 的提醒：</p>
<p>其他股票分析师最近也对该股票发布了研究报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Spero Therapeutics 股票的 “卖出（d-）” 评级。Zacks Research 在 10 月 13 日的研究报告中将 Spero Therapeutics 的评级从 “强力买入” 下调至 “持有”。一位研究分析师给予该股票 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，共识目标价为 5.00 美元。</p>
<p><strong>查看我们对 SPRO 的最新分析</strong></p>
<h2>Spero Therapeutics 股价下跌 0.9%</h2>
<p>SPRO 股票周五开盘价为 2.26 美元。该公司的 50 日简单移动平均为 2.31 美元，200 日简单移动平均为 2.28 美元。Spero Therapeutics 的 12 个月低点为 0.51 美元，12 个月高点为 3.22 美元。该公司的市值为 1.2733 亿美元，市盈率为-2.86，贝塔值为 1.48。</p>
<p>Spero Therapeutics（纳斯达克代码：SPRO - 获取免费报告）最近于 11 月 13 日发布了季度财报。该公司报告季度每股收益为（0.13 美元），超出分析师共识预期的（0.25 美元）0.12 美元。该公司季度收入为 544 万美元，而分析师预期为 1200 万美元。Spero Therapeutics 的净利润率为-108.11%，股本回报率为-125.91%。平均而言，股票分析师预测 Spero Therapeutics 在当前财年将发布-1.2 的每股收益。</p>
<h2>内部人士买卖情况</h2>
<p>在相关消息中，内部人士 Esther Rajavelu 于 11 月 7 日星期五出售了 40270 股该股票。股票以平均价格 2.37 美元出售，总价值为 95439.90 美元。出售后，该内部人士在公司持有 869450 股，价值约 2060596.50 美元。这笔交易代表其持股比例减少了 4.43%。该出售在向 SEC 的备案中披露，相关信息可通过 SEC 网站获取。公司内部人士持有该公司 5.50% 的股份。</p>
<h2>机构投资者对 Spero Therapeutics 的看法</h2>
<p>大型投资者最近增加或减少了对该公司的持股。Invesco Ltd.在第二季度购买了 Spero Therapeutics 的新股份，价值约 43000 美元。Dimensional Fund Advisors LP 在第三季度购买了 Spero Therapeutics 的新头寸，价值约 55000 美元。Assenagon Asset Management S.A.在第三季度购买了 Spero Therapeutics 的股份，价值约 70000 美元。Quadrature Capital Ltd 在第二季度购买了 Spero Therapeutics 的新头寸，价值约 90000 美元。最后，Two Sigma Investments LP 在第三季度购买了 Spero Therapeutics 的新股份，价值约 93000 美元。对冲基金和其他机构投资者持有该公司 25.60% 的股份。</p>
<h2>Spero Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Spero Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于在美国识别、开发和商业化针对多重耐药（MDR）细菌感染和罕见疾病的新治疗方法。该公司的产品候选包括：用于治疗复杂尿路感染（包括成人肾盂肾炎）的口服碳青霉烯类抗生素 tebipenem pivoxil hydrobromide（HBr）；针对包括碳青霉烯耐药肠杆菌（CRE）、鲍曼不动杆菌和铜绿假单胞菌等 MDR 革兰氏阴性病原体的静脉给药抗生素 SPR206，以及医院环境中的阴性细菌感染；以及用于治疗非结核分枝杆菌肺病的新型口服抗生素 SPR720。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 Spero Therapeutics</li>
<li>如何选择顶级评级股票</li>
<li>Rocket Lab 的大反弹？分析师认为下跌是个机会</li>
<li>金融服务股票投资</li>
<li>Meta 的 AI 时刻？新的 SAM 3 模型让华尔街变得乐观</li>
<li>3 只杂货股票证明它们仍然是必需品</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Spero Therapeutics 吗？</h2>
<p>在考虑 Spero Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Spero Therapeutics 并不在名单上。</p>
<p>虽然 Spero Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SPRO

<p>Spero Therapeutics（纳斯达克代码：SPRO）被 Wall Street Zen 从 “买入” 评级下调至 “持有” 评级。其他分析师也发布了类似的下调，Weiss Ratings 重申 “卖出” 评级，Zacks Research 下调至 “持有”。该股票开盘价为 2.26 美元，市值为 1.2733 亿美元。内部人士 Esther Rajavelu 出售了股份，减少了 4.43% 的持股比例。机构投资者已调整了在该公司的持股</p>

<p>Spero Therapeutics (NASDAQ:SPRO - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report issued to clients and investors on Saturday.</p>
<div class="lb-trans"><p>Spero Therapeutics（纳斯达克代码：SPRO - 获取免费报告）在华尔街 Zen 的股票分析师的研究报告中，将其评级从 “买入” 下调至 “持有”，该报告于周六发给客户和投资者。</p>
</div><p>Get <strong>Spero Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Spero Therapeutics</strong> 的提醒：</p>
</div><p>Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Spero Therapeutics in a research report on Wednesday, October 8th. Zacks Research downgraded Spero Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, October 13th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of &#34;Hold&#34; and a consensus target price of $5.00.</p>
<div class="lb-trans"><p>其他股票分析师最近也对该股票发布了研究报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Spero Therapeutics 股票的 “卖出（d-）” 评级。Zacks Research 在 10 月 13 日的研究报告中将 Spero Therapeutics 的评级从 “强力买入” 下调至 “持有”。一位研究分析师给予该股票 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，共识目标价为 5.00 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on SPRO</strong></p>
<div class="lb-trans"><p><strong>查看我们对 SPRO 的最新分析</strong></p>
</div><h2>Spero Therapeutics Trading Down 0.9%</h2>
<div class="lb-trans"><h2>Spero Therapeutics 股价下跌 0.9%</h2>
</div><p>Shares of SPRO stock opened at $2.26 on Friday. The firm has a fifty day simple moving average of $2.31 and a two-hundred day simple moving average of $2.28. Spero Therapeutics has a 12 month low of $0.51 and a 12 month high of $3.22. The firm has a market capitalization of $127.33 million, a PE ratio of -2.86 and a beta of 1.48.</p>
<div class="lb-trans"><p>SPRO 股票周五开盘价为 2.26 美元。该公司的 50 日简单移动平均为 2.31 美元，200 日简单移动平均为 2.28 美元。Spero Therapeutics 的 12 个月低点为 0.51 美元，12 个月高点为 3.22 美元。该公司的市值为 1.2733 亿美元，市盈率为-2.86，贝塔值为 1.48。</p>
</div><p>Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.12. The firm had revenue of $5.44 million for the quarter, compared to analyst estimates of $12.00 million. Spero Therapeutics had a negative net margin of 108.11% and a negative return on equity of 125.91%. On average, equities analysts predict that Spero Therapeutics will post -1.2 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Spero Therapeutics（纳斯达克代码：SPRO - 获取免费报告）最近于 11 月 13 日发布了季度财报。该公司报告季度每股收益为（0.13 美元），超出分析师共识预期的（0.25 美元）0.12 美元。该公司季度收入为 544 万美元，而分析师预期为 1200 万美元。Spero Therapeutics 的净利润率为-108.11%，股本回报率为-125.91%。平均而言，股票分析师预测 Spero Therapeutics 在当前财年将发布-1.2 的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖情况</h2>
</div><p>In related news, insider Esther Rajavelu sold 40,270 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $2.37, for a total value of $95,439.90. Following the sale, the insider owned 869,450 shares in the company, valued at approximately $2,060,596.50. This trade represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 5.50% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Esther Rajavelu 于 11 月 7 日星期五出售了 40270 股该股票。股票以平均价格 2.37 美元出售，总价值为 95439.90 美元。出售后，该内部人士在公司持有 869450 股，价值约 2060596.50 美元。这笔交易代表其持股比例减少了 4.43%。该出售在向 SEC 的备案中披露，相关信息可通过 SEC 网站获取。公司内部人士持有该公司 5.50% 的股份。</p>
</div><h2>Institutional Investors Weigh In On Spero Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Spero Therapeutics 的看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the company. Invesco Ltd. bought a new stake in Spero Therapeutics in the 2nd quarter worth approximately $43,000. Dimensional Fund Advisors LP bought a new position in Spero Therapeutics during the third quarter valued at approximately $55,000. Assenagon Asset Management S.A. purchased a new position in shares of Spero Therapeutics during the third quarter worth approximately $70,000. Quadrature Capital Ltd purchased a new position in shares of Spero Therapeutics during the second quarter worth approximately $90,000. Finally, Two Sigma Investments LP bought a new stake in shares of Spero Therapeutics in the 3rd quarter worth approximately $93,000. Hedge funds and other institutional investors own 25.60% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对该公司的持股。Invesco Ltd.在第二季度购买了 Spero Therapeutics 的新股份，价值约 43000 美元。Dimensional Fund Advisors LP 在第三季度购买了 Spero Therapeutics 的新头寸，价值约 55000 美元。Assenagon Asset Management S.A.在第三季度购买了 Spero Therapeutics 的股份，价值约 70000 美元。Quadrature Capital Ltd 在第二季度购买了 Spero Therapeutics 的新头寸，价值约 90000 美元。最后，Two Sigma Investments LP 在第三季度购买了 Spero Therapeutics 的新股份，价值约 93000 美元。对冲基金和其他机构投资者持有该公司 25.60% 的股份。</p>
</div><h2>Spero Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Spero Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.</p>
<div class="lb-trans"><p>Spero Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于在美国识别、开发和商业化针对多重耐药（MDR）细菌感染和罕见疾病的新治疗方法。该公司的产品候选包括：用于治疗复杂尿路感染（包括成人肾盂肾炎）的口服碳青霉烯类抗生素 tebipenem pivoxil hydrobromide（HBr）；针对包括碳青霉烯耐药肠杆菌（CRE）、鲍曼不动杆菌和铜绿假单胞菌等 MDR 革兰氏阴性病原体的静脉给药抗生素 SPR206，以及医院环境中的阴性细菌感染；以及用于治疗非结核分枝杆菌肺病的新型口服抗生素 SPR720。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Spero Therapeutics</li>
<li>How to Choose Top Rated Stocks</li>
<li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li>
<li>Financial Services Stocks Investing</li>
<li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Spero Therapeutics</li>
<li>如何选择顶级评级股票</li>
<li>Rocket Lab 的大反弹？分析师认为下跌是个机会</li>
<li>金融服务股票投资</li>
<li>Meta 的 AI 时刻？新的 SAM 3 模型让华尔街变得乐观</li>
<li>3 只杂货股票证明它们仍然是必需品</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Spero Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Spero Therapeutics 吗？</h2>
</div><p>Before you consider Spero Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Spero Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spero Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Spero Therapeutics 并不在名单上。</p>
</div><p>While Spero Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Spero Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Spero Therapeutics（纳斯达克股票代码：SPRO）的股票评级被华尔街 Zen 下调